Kirk A D, Baldwin W M, Cascalho M I, Chong A S, Sykes M, West L J
The Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Am J Transplant. 2007 Jun;7(6):1464-70. doi: 10.1111/j.1600-6143.2007.01815.x.
There is growing awareness that B cells and alloantibodies are important mediators of both acute and chronic allograft injury. Unfortunately, few therapies are clinically available to mitigate the function of B cells or the effects of established alloantibody. As a result, many sensitized people await transplantation without a suitable donor, and several rejection syndromes are emerging that appear to involve B cells either as antibody producers or as antigen-presenting cells. In recognition of this unmet need in transplantation, the American Society of Transplantation organized a Symposium on B cells in Organ Transplantation to foster interest in this topic amongst basic researchers attending the annual meeting of the American Association of Immunologists. This manuscript will give an overview of the presentations from this symposium including the current risks of allosensitization, adaptive accommodation, approaches toward B-cell tolerance for allo- and xenoantigens and clinical application of these concepts in ABO incompatible neonatal cardiac transplantation.
人们越来越意识到,B细胞和同种异体抗体是急性和慢性移植器官损伤的重要介质。不幸的是,临床上几乎没有可用的疗法来减轻B细胞的功能或已形成的同种异体抗体的影响。因此,许多致敏者在等待移植时没有合适的供体,并且出现了几种排斥综合征,这些综合征似乎涉及作为抗体产生者或抗原呈递细胞的B细胞。认识到移植领域的这一未满足需求,美国移植学会组织了一次器官移植中B细胞专题研讨会,以激发参加美国免疫学家协会年会的基础研究人员对该主题的兴趣。本手稿将概述本次研讨会的报告内容,包括当前同种异体致敏的风险、适应性调节、针对同种异体和异种抗原的B细胞耐受方法以及这些概念在ABO血型不相容的新生儿心脏移植中的临床应用。